NOVATO, Calif., Aug. 30, 2011 /PRNewswire/ — BioMarin
Pharmaceutical Inc. (Nasdaq:
BMRN) today announced that Jeffrey Cooper, Chief Financial
Officer of BioMarin, will present a company update at the Baird
Health Care Conference in New York on Wednesday, September 7, 2011
at 9:30 a.m. ET.
Interested parties may access a live audio webcast of the
conference call via the investor section of the BioMarin website,
www.BMRN.com. A replay of the
call will be archived on the site for one week following the
call.
About BioMarinBioMarin develops and commercializes innovative
biopharmaceuticals for serious diseases and medical conditions. The
company’s product portfolio comprises four approved products and
multiple clinical and pre-clinical product candidates. Approved
products include Naglazyme® (galsulfase) for
mucopolysaccharidosis VI (MPS VI), a product wholly developed and
commercialized by BioMarin; Aldurazyme® (laronidase) for
mucopolysaccharidosis I (MPS I), a product which BioMarin developed
through a 50/50 joint venture with Genzyme Corporation; Kuvan®
(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU),
developed in partnership with Merck Serono, a division of Merck
KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine
phosphate), which has been approved by the European Commission for
the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product
candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which
is currently in Phase III clinical development for the treatment of
MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia
lyase), which is currently in Phase II clinical development for the
treatment of PKU; BMN-701, a novel fusion protein of insulin-like
growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is
currently in Phase I/II clinical developmen
‘/>”/>
SOURCE
